20
ALL20
Hansoh PharmaYear
20
ALL1
20254
20245
20233
20224
20213
2020DEALS // DEV.
20
ALL15
Deals5
DevelopmentsCountry
18
ALL6
CHINA2
SOUTH KOREA6
U.S.A4
UNITED KINGDOM20
ALL1
Biotheus1
EQRx2
GSK1
Inapplicable1
Keros Therapeutics1
Merck & Co2
NiKang Therapeutics2
Not Applicable1
OliX Pharmaceutical2
Scynexis4
Silence Therapeutics1
Terns Pharmaceuticals1
TiumbioTherapeutic Area
20
ALL2
Cardiology/Vascular Diseases1
Genetic Disease3
Infections and Infectious Diseases1
Neurology1
Obstetrics/Gynecology (Women’s Health)9
Oncology3
TechnologyStudy Phase
20
ALL3
Approved1
Phase III4
Phase II1
Phase I/ Phase II2
Phase I1
IND Enabling7
Preclinical1
DiscoveryDeal Type
16
ALL8
Collaboration1
Inapplicable4
Licensing Agreement3
PartnershipProduct Type
20
ALL6
Large molecule4
Oligonucleotide1
Other Small Molecule9
Small moleculeDosage Form
14
ALL3
Infusion2
Oral1
Oral Tablet1
Subcutaneous Injection2
Tablet1
Tablet, Film Coated4
UndisclosedLead Product
20
ALL1
Aumolertinib1
Aumolertinib Mesylate1
HS-105181
HS-105351
HS-200892
HS-200931
HS-201172
Ibrexafungerp Citrate1
KER-0501
Merigolix1
NKT-19921
NKT21522
SLN-HAN-11
TRN-0006322
Undisclosed1
siRNA-based TherapyTarget
10
ALL1
1,3-Beta-D-glucan synthase1
BCR-ABL2
CIDEB1
EGFR1
GnRH1
HIF-2 alpha1
TGF beta2
UndisclosedLead Product(s) : Merigolix
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Hansoh Expands Merigolix use with ART Development Initiation
Details : HS-10518 (merigolix) is a once-daily, oral gonadotropin-releasing hormone (GnRH) receptor antagonist, which is being investigated for improvement of pregnancy rate per cycle.
Product Name : HS-10518
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 20, 2025
Lead Product(s) : Merigolix
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HS-10535
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Preclinical
Sponsor : Merck & Co
Deal Size : $2,012.0 million
Deal Type : Licensing Agreement
Merck Signs Up to $2 Bln Obesity Drug Deal with Chinese Biotech Hansoh
Details : Under the agreement, Hansoh has granted Merck an exclusive global license to develop, manufacture and commercialize HS-10535, an investigational preclinical oral small molecule GLP-1 receptor agonist.
Product Name : HS-10535
Product Type : Small molecule
Upfront Cash : $112.0 million
December 18, 2024
Lead Product(s) : HS-10535
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Preclinical
Sponsor : Merck & Co
Deal Size : $2,012.0 million
Deal Type : Licensing Agreement
Hansoh’s HS-20093 Shows Potential in Second-Line SCLC Therapy in China
Details : HS-20093 is a novel B7-H3-targeted ADC composed of a fully-humanized anti-B7-H3 monoclonal antibody covalently linked to TOPOi payload and being developed in China for small cell lung cancer.
Product Name : HS-20093
Product Type : Large molecule
Upfront Cash : Not Applicable
November 22, 2024
Lead Product(s) : siRNA-based Therapy
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Recipient : Silence Therapeutics
Deal Size : $1,316.0 million
Deal Type : Collaboration
Silence Therapeutics Achieves Research Milestone Payment from Hansoh Pharma Collaboration
Details : The collaboration aims to develop siRNAs leveraging Silence’s mRNAi GOLD platform for three undisclosed targets. Silence has exclusive rights to the first two targets in all territories except china.
Product Name : Undisclosed
Product Type : Large molecule
Upfront Cash : $16.0 million
June 24, 2024
Lead Product(s) : siRNA-based Therapy
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Recipient : Silence Therapeutics
Deal Size : $1,316.0 million
Deal Type : Collaboration
Biotheus Expands Partnership with Hansoh for EGFR/cMET Bispecific Antibody Conjugates
Details : Through the partnership, Biotheus will grant Hansoh Pharma a license to use the lead product PM1080 (HS-20117) for EGFR/c-MET expressing neoplasms and including Non-Small-Cell Lung Carcinoma.
Product Name : PM1080
Product Type : Large molecule
Upfront Cash : Undisclosed
March 15, 2024
GSK Enters Exclusive License Agreement with Hansoh for HS-20093
Details : Under the agreement, GSK will obtain exclusive worldwide rights to progress development and commercialisation for HS-20093, a B7-H3 targeted antibody-drug conjugate (ADC) utilising a clinically validated topoisomerase inhibitor (TOPOi) payload, in advanc...
Product Name : HS-20093
Product Type : Large molecule
Upfront Cash : $185.0 million
December 20, 2023
GSK Enters Exclusive License Agreement with Hansoh for HS-20089
Details : Under the agreement, GSK will obtain rights to progress development and commercialisation for HS-20089, a B7-H4 targeted antibody-drug conjugate currently in phase I clinical trials in China, in ovarian and endometrial cancer.
Product Name : HS-20089
Product Type : Large molecule
Upfront Cash : $85.0 million
October 20, 2023
Lead Product(s) : Ibrexafungerp Citrate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Recipient : Scynexis
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Brexafemme (ibrexafungerp), a novel glucan synthase inhibitor, approved for vulvovaginal candidiasis and RVVC, is being develop in phase 3 trials for the potential treatment of invasive candidiasis.
Product Name : Brexafemme
Product Type : Small molecule
Upfront Cash : Not Applicable
July 20, 2023
Lead Product(s) : Ibrexafungerp Citrate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Recipient : Scynexis
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Study Phase : Preclinical
Recipient : Silence Therapeutics
Deal Size : $1,316.0 million
Deal Type : Collaboration
Details : The collaboration aims to develop siRNAs (short interfering RNAs) leveraging Silence’s proprietary mRNAi GOLD™ platform for three undisclosed targets. Silence has exclusive rights to the first two targets in all territories except the China region.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : $16.0 million
July 11, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Technology
Highest Development Status : Preclinical
Recipient : Silence Therapeutics
Deal Size : $1,316.0 million
Deal Type : Collaboration
TiumBio and Hansoh Pharma Announce Clinical Trial Approval of 'HS-10518/TU2670' from NMPA in China
Details : TU2670 is an orally active non-peptide GnRH antagonist currently undergoing a Phase 2a clinical study in the EU for the treatment of moderate to severe pain associated with endometriosis.
Product Name : TU2670
Product Type : Small molecule
Upfront Cash : Not Applicable
July 05, 2023